News & Press Releases
Filter by:
FERC in 2026: Rising Costs Cloud Regulators’ Options on Data Centers, Transmission and More
January 29, 2026
Utility Dive featured insights from Digital Infrastructure Co-chair Steven Shparber in an article focused on what to expect from FERC in 2026, including the agency’s focus on ensuring recent interconnection and transmission changes are successfully implemented.
Member Theresa Carnegie, Associate Hassan Shaikh, and Law Clerk Grace Callander wrote an article published by the Employee Benefit Plan Review focused on the key provisions of a set of new regulations for PBMs and health plans operating in California, including requirements related to governance and oversight, transparency and pricing, and enforcement.
States Target AI That Tells Companies How Much to Pay Workers
January 21, 2026
Member Jen Rubin was quoted by Bloomberg Law in an article about how a number of states, including California, Colorado, Georgia, and Illinois, are pushing for regulation around the use of AI systems in employee compensation decisions, among other employment contexts. The states’ efforts aim to prevent discrimination and unfair wage practices.
Trump’s Drug Pricing Proposals Draw Legal Questions from Pharma
January 20, 2026
Member Theresa Carnegie was quoted by Bloomberg Law in an article about the Trump Administration’s new drug-pricing models, which aim to align Medicare drug prices with lower international prices. The article notes that the pharmaceutical industry is raising legal questions about whether CMS has the authority to implement the two new pricing demonstrations.
Decumulation-Friendly 401(k) Retirement Plans
January 20, 2026
The Journal of Pension Benefits published an article written by Of Counsel Michelle Capezza about 401(k) retirement plans and the need to assist plan participants in managing their retirement assets in the decumulation phase. Michelle writes that plan sponsors should consider how to improve their retirement programs to address this need.
Member Ken Jenkins was quoted in an article by UCSF Innovation Ventures focused on an FDA approved autoimmune drug, Rilzabrutinib, which went from a university invention to a marketable drug.
